McKesson Corporation $MCK Shares Purchased by James Hambro & Partners LLP

James Hambro & Partners LLP lifted its stake in McKesson Corporation (NYSE:MCK) by 3.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 138,952 shares of the company’s stock after purchasing an additional 4,301 shares during the period. McKesson comprises about 4.1% of James Hambro & Partners LLP’s investment portfolio, making the stock its 11th largest position. James Hambro & Partners LLP owned 0.12% of McKesson worth $118,760,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently added to or reduced their stakes in MCK. Rosenberg Matthew Hamilton lifted its position in shares of McKesson by 2.8% during the 3rd quarter. Rosenberg Matthew Hamilton now owns 406 shares of the company’s stock worth $347,000 after buying an additional 11 shares in the last quarter. Avail Investment Partners LLC boosted its stake in shares of McKesson by 1.7% in the 3rd quarter. Avail Investment Partners LLC now owns 662 shares of the company’s stock worth $566,000 after buying an additional 11 shares during the last quarter. Anchyra Partners LLC grew its holdings in shares of McKesson by 1.0% in the first quarter. Anchyra Partners LLC now owns 1,174 shares of the company’s stock valued at $1,016,000 after acquiring an additional 12 shares in the last quarter. SJS Investment Consulting Inc. grew its holdings in shares of McKesson by 7.5% in the first quarter. SJS Investment Consulting Inc. now owns 172 shares of the company’s stock valued at $149,000 after acquiring an additional 12 shares in the last quarter. Finally, SMART Wealth LLC increased its position in shares of McKesson by 3.4% during the first quarter. SMART Wealth LLC now owns 366 shares of the company’s stock valued at $317,000 after acquiring an additional 12 shares during the last quarter. Hedge funds and other institutional investors own 85.07% of the company’s stock.

McKesson Price Performance

NYSE:MCK traded down $0.82 on Monday, reaching $1,004.02. 237,748 shares of the company’s stock were exchanged, compared to its average volume of 927,037. The firm has a market cap of $117.06 billion, a price-to-earnings ratio of 26.85, a P/E/G ratio of 2.00 and a beta of 0.30. McKesson Corporation has a 52 week low of $723.68 and a 52 week high of $1,014.99. The stock has a fifty day simple moving average of $897.66 and a 200-day simple moving average of $837.34.

McKesson (NYSE:MCK) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $9.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.56 by $0.37. The company had revenue of $105.38 billion for the quarter, compared to analyst estimates of $103.88 billion. McKesson had a net margin of 1.12% and a negative return on equity of 253.21%. The company’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $8.26 earnings per share. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. As a group, sell-side analysts predict that McKesson Corporation will post 44.71 EPS for the current year.

McKesson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, October 1st. Investors of record on Tuesday, September 1st were paid a $0.94 dividend. The ex-dividend date was Tuesday, September 1st. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. This is a positive change from McKesson’s previous quarterly dividend of $0.82. McKesson’s dividend payout ratio (DPR) is presently 10.06%.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Evercore reiterated an “outperform” rating and set a $950.00 target price (down from $1,000.00) on shares of McKesson in a research note on Thursday, August 6th. Weiss Ratings upgraded shares of McKesson from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, September 4th. UBS Group increased their price target on shares of McKesson from $1,080.00 to $1,200.00 and gave the company a “buy” rating in a research report on Friday. Wells Fargo & Company raised their price objective on shares of McKesson from $812.00 to $933.00 and gave the stock an “equal weight” rating in a report on Tuesday, August 11th. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $845.00 price objective on shares of McKesson in a research report on Monday, September 14th. Fifteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, McKesson presently has an average rating of “Moderate Buy” and an average price target of $990.35.

Insiders Place Their Bets

In other McKesson news, Director Bradley Lerman sold 301 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $892.33, for a total transaction of $268,591.33. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO B Jr sold 111 shares of the stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $891.45, for a total value of $98,950.95. Following the sale, the chief accounting officer owned 521 shares in the company, valued at approximately $464,445.45. This represents a 17.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.06% of the company’s stock.

McKesson Company Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and medical products to pharmacies, hospitals, health systems, physicians and other healthcare providers. The company also provides technology, data and business solutions designed to support prescription management, pharmacy operations and patient care.

McKesson’s principal activities include pharmaceutical distribution, medical-surgical supply distribution, specialty pharmaceutical services and oncology care support.